Eckert & Ziegler Radiopharma, the production arm of isotope technology firm Eckert & Ziegler, has inked a supply deal with Atom Mines for the radiopharmaceutical ytterbium-176.
Ytterbium-176 is a necessary precursor to lutetium-177, which is used for many cancer therapies, according to the firm. But the world supply of ytterbium-176 has been limited.
Eckert & Ziegler Radiopharma and Atom Mines have developed a new technology that can increase production of the isotope, which will allow for the manufacture of lutetium-177 in larger quantities, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
